6-{[[(2-methoxy-5-trifluoromethyl)phenyl]amino]methyl}-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine | 174654-98-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-{[[(2-methoxy-5-trifluoromethyl)phenyl]amino]methyl}-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine
• 英文别名: SoRI 8897；6-[[2-Methoxy-5-(trifluoromethyl)anilino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
• CAS: 174654-98-9
• 化学式: C₁₇H₁₇F₃N₆O
• 分子量: 378.357
• InChiKey: XNEOAXKYJADVSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  2-甲氧基-5-三氟甲基苯胺 、 2,4-diamino-5-methyl-5-deaza-6-bromomethylpteridine 生成 6-{[[(2-methoxy-5-trifluoromethyl)phenyl]amino]methyl}-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine
  参考文献：
  名称：

  2,4-diamino-5-deazapteridine 衍生物的抗分枝杆菌活性及其对分枝杆菌二氢叶酸还原酶的影响。

  摘要：

  开发用于鸟分枝杆菌复合体 (MAC) 感染的新抗分枝杆菌药物对于同时感染人类免疫缺陷病毒的人来说尤其重要。本研究的目的是评估 2, 4-diamino-5-methyl-5-deazapteridines (DMDPs) 对 MAC 的体外活性，并评估它们对 MAC 二氢叶酸还原酶重组酶 (rDHFR) 的活性。最初评估了 77 种 DMDP 衍生物对一到三株 MAC（NJ168、NJ211 和/或 NJ3404）的体外活性。用 10 倍稀释的药物和比色法（Alamar Blue）微量稀释肉汤测定法测定 MIC。还确定了 MAC rDHFR 50% 抑制浓度与人 rDHFR 的抑制浓度。蝶啶部分第 5 位的取代基包括 -CH(3)、-CH(2)CH(3) 和 -CH(2)OCH(3) 基团。此外，不同的取代和未取代的芳基通过 -CH(2)NH、-CH(2)N(CH(3))、-CH(2)CH(2)

  DOI：

  10.1128/aac.44.10.2784-2793.2000

文献信息

• Lipophilic Antifolates as Agents against Opportunistic Infections. 1. Agents Superior to Trimetrexate and Piritrexim against <i>Toxoplasma gondii</i> and <i>Pneumocystis carinii</i> in <i>in Vitro</i> Evaluations
  作者：James R. Piper、Cheryl A. Johnson、Charles A. Krauth、Ronald L. Carter、Carla A. Hosmer、Sherry F. Queener、Susan E. Borotz、Elmer R. Pfefferkorn

  DOI：10.1021/jm950760y

  日期：1996.3.15

  2,4-Diaminopteridines (21 compounds) and 2,4-diamino-5-methyl-5-deazapteridines (34 compounds) along with three 2,4-diamino-5-unsubstituted-5-dieazapteridines and four 2,4-diaminoquinazolines, each with an aryl group attached to the 6-position of the heterocyclic moiety through a two-atom bridge (either CH2NH, CH2N(CH3), CH2S, or CH2CH2), were synthesized and evaluated as inhibitors of the growth of Toxoplasma gondii in culture and as inhibitors of dihydrofolate reductase enzymes from T. gondii, Pneumocystis carinii, and rat liver. Exceptionally high levels of combined potency and selectivity as growth inhibitors of T. gondii and as inhibitors of the microbial enzymes relative to the mammalian enzyme were found among the 5-methyl-5-deazapteridines but not for the other heterocyclic types. Thirty of the 34 5-methyl-5-deaza compounds gave growth inhibition IC50 values lower than that of pyrimethamine (0.4 mu M) with 14 compounds below 0.1 mu M, values that compare favorably with those for piritrexim and trimetrexate (both near 0.02 mu M). As inhibitors of T. gondii DHFR, all but three of the 34 5-methyl-5-deaza compounds gave IC50 values in the order of magnitude with those of piritrexim (0.017 mu M) and trimetrexate (0.010 mu M), and 17 compounds of this group gave IC50 values versus P. carinii DHFR similarly comparable with those of piritrexim (0.031 mu M) and trimetrexate (0.042 mu M). Thirteen of these congeners gave both T. gondii growth inhibition and DHFR inhibition IC50 values of 0.10 mu M or less, thus indicating facile penetration of the cell membrane. Eleven of these inhibitors of both T. gondii growth and DHFR have selectivity ratios (IC50 rat liver divided by IC50 T gondii) of 5 or greater for the parasite DHFR. The highest selectivity ratio of nearly 100 belongs to the 5-methyl-5-deaza compound whose B-substituent is CH2CH2C6H3(OCH3)(2)-2,5. This compound is over 10(3)-fold more selective for T. gondii DHFR than bridge homologue piritrexim (selectivity ratio 0.088), a compound now in clinical trials. The candidate with CH2NHC6H3(CH3)(2)-2,5 in the 6-position gave the highest P. carinii DHFR selectivity ratio of 4.0, which is about 60-fold more selective than trimetrexate (0.071) and 80-fold more selective than piritrexim (0.048) toward this enzyme. The 10 best compounds with respect to potency and selectivity includes six compounds bearing 2,5-disubstituted phenyl groups in the side chain (with little, if any, difference in effects of methyl, methoxy, or ethoxy), two side chains bearing 1-naphthyl groups, and two with 5,6,7,8-tetrahydro-1-naphthyl groups. Bridge groups represented in the 10 choice compounds are CH2NH, CH2N(CH3), CH2CH2, and CH2S. The high levels of both potency and selectivity among these agents suggest that in vivo studies now underway may lead to agents that could replace trimetrexate and piritrexim in treatment of toxoplasmosis and P. carinii pneumonia.
• Antimycobacterial Activities of 2,4-Diamino-5-Deazapteridine Derivatives and Effects on Mycobacterial Dihydrofolate Reductase
  作者：William J. Suling、Lainne E. Seitz、Vibha Pathak、Louise Westbrook、Esther W. Barrow、Sabrina Zywno-van-Ginkel、Robert C. Reynolds、J. Robert Piper、William W. Barrow

  DOI：10.1128/aac.44.10.2784-2793.2000

  日期：2000.10

  were active against MAC NJ168 at concentrations of < or =13 microg/ml. Depending on the MAC strain used, 81 to 87% had MICs of < or =1.3 microg/ml. Twenty-one derivatives were >100-fold more active against MAC rDHFR than against human rDHFR. In general, selectivity was dependent on the composition of the two-atom bridge at position 6 and the attached aryl group with substitutions at the 2' and 5' positions

  开发用于鸟分枝杆菌复合体 (MAC) 感染的新抗分枝杆菌药物对于同时感染人类免疫缺陷病毒的人来说尤其重要。本研究的目的是评估 2, 4-diamino-5-methyl-5-deazapteridines (DMDPs) 对 MAC 的体外活性，并评估它们对 MAC 二氢叶酸还原酶重组酶 (rDHFR) 的活性。最初评估了 77 种 DMDP 衍生物对一到三株 MAC（NJ168、NJ211 和/或 NJ3404）的体外活性。用 10 倍稀释的药物和比色法（Alamar Blue）微量稀释肉汤测定法测定 MIC。还确定了 MAC rDHFR 50% 抑制浓度与人 rDHFR 的抑制浓度。蝶啶部分第 5 位的取代基包括 -CH(3)、-CH(2)CH(3) 和 -CH(2)OCH(3) 基团。此外，不同的取代和未取代的芳基通过 -CH(2)NH、-CH(2)N(CH(3))、-CH(2)CH(2)